Reaktion #1122380

ord-217b1a61144a42bb88d174d46f96e085

Reaktionsgleichung

CN1CCN(Cc2ccc(OC3CNC3)cc2F)CC1
29D
CN1CCN(Cc2ccc(OC3CNC3)cc2F)CC1
1-(4-(Azetidin-3-yloxy)-2-fluorobenzyl)-4-methylpiperazine
CCOC(=O)c1nnc(-c2ccc(OC)cc2)o1
ethyl 5-(4-methoxyphenyl)-1,3,4-oxadiazole-2-carboxylate
CN1CCN(Cc2ccc(OC3CN(C(=O)c4nnc(-c5ccccc5)o4)C3)cc2F)CC1
29
Ausbeute 32.0%
CN1CCN(Cc2ccc(OC3CN(C(=O)c4nnc(-c5ccccc5)o4)C3)cc2F)CC1
1-[2-Fluoro-4-({1-[(5-phenyl-1,3,4-oxadiazol-2-yl)carbonyl]azetidin-3-yl}oxy)benzyl]-4-methylpiperazine
Ausbeute 32.0%

Reaktionsbedingungen

Detaillierte Bedingungen
See reaction.notes.procedure_details.

Vorschrift

Using a similar protocol as described in Example 10 employing 29D (0.10 g, 0.36 mmol) and ethyl 5-(4-methoxyphenyl)-1,3,4-oxadiazole-2-carboxylate (0.11 g, 0.43 mmol) as starting materials afforded 52 mg (30%) of 29 as a foam.

Quelle

DOI: 10.6084/m9.figshare.5104873.v1Patent: US08546375B2uspto-grants-2013_10